环孢素A与他克莫司应用于肝移植受者的药物经济学评价  

Pharmacoeconomics evaluation of cyclosporine A and tacrolimus for recipient in liver transplantation

作　　者：杨晨[1,2] 黄海[2] 

机构地区：[1]南方医科大学研究生学院,广州510515 [2]广州军区广州总医院药剂科,广州510010

出　　处：《实用药物与临床》2012年第12期784-786,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的评价环孢素A胶囊与他克莫司胶囊治疗肝移植受体排斥的经济性。方法选择在我院接受肝移植,并于2010年1月-2011年12月在门诊继续治疗的患者共60例,比较用药半年后的临床疗效、不良反应及用药成本,运用药物经济学的最小成本分析法对两种药物的经济效果进行评价。结果环孢素A胶囊组总有效率为78%,他克莫司胶囊组为86%,两组比较差异无统计学意义(P>0.05),环孢素A胶囊组的不良反应发生率较他克莫司胶囊组低。成本/效果比(C/E):环孢素A胶囊组为55.81,他克莫司胶囊组为46.19。结论与环孢素A胶囊比较,他克莫司胶囊用于肝移植受者更为经济有效。Objective To evaluate the economics of cyclosporine A capsule and tacrolimus capsule in rejection mode of liver transplantation.Methods 60 outpatients receiving liver transplantation in our hospital from January 2010 to December 2011 were chose,and the therapeutic effect,ADR and cost after using the two drugs were evaluated by cost-minimization analysis of pharmacoeconomics.Results The total effective rate in cyclosporine A capsule group and tacrolimus capsule group were 78% and 86% respectively（P0.05）,and the Cost/Effect ratio（C/E）were 55.81 and 46.19 respectively.The ADR rate of cyclosporine A capsule group was lower than that of tacrolimus capsule group.Conclusion Compared with cyclosporine A capsule,tacrolimus capsule is more economical for recipient in liver transplantation.

关 键 词：环孢素A 他克莫司 肝移植 药物经济学 

分 类 号：R657.3[医药卫生—外科学]